Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
The Humble Economist: Tony Culyer on Health, Health Care and Social Decision Making
1 November 2012
The Humble Economist is an outstanding collection of the most important essays by Prof Tony Culyer, a founding father of health economics. It distils a powerful…
Value Based Pricing in Sweden: Lessons for Design?
11 January 2012
In this Seminar Briefing, Ulf Persson recounts Sweden’s experience with its approach to value based pricing (VBP). The model is a flexible approach that gives weight…
Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
1 April 2012
Diagnostics not only facilitate health gain and cost savings, but also provide information to inform patients’ decisions on interventions and to clarify how their behaviour may…
The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?
1 February 2012
Interest is growing in schemes that involve “paying for pills by results”, that is, “paying for performance” rather than merely “paying for pills”. Despite its intuitive…
Report of the Office of Health Economics Commission on Competition in the NHS
1 January 2012
This report is based on the deliberations of the OHE Commission on Competition that was assembled in early 2011 “to consider the circumstances where competition between…
Time Trends in NICE HTA Decisions
1 January 2012
According to the 1999 UK Department of Health consultation document, the fundamental purpose of the National Institute for Health and Clinical Excellence (NICE) was to reduce…
Upcoming OHE Seminars: MCDA and R&D Productivity
16 November 2011
Join OHE for two exciting seminars, one on MCDA and the other on shifts in investment in R&D.
Valuing Health at the End of Life: Public Preferences
13 October 2011
In 2009, the UK’s National Institute for Health and Clinical Excellence (NICE) issued supplementary advice that its Appraisal Committees are to consider when assessing treatments that…
Join OHE at ISPOR: MCDA, Risk Sharing and Value-Based Pricing
4 October 2011
Join OHE at ISPOR to discuss multiple criteria decision analysis, value based pricing, risk sharing, post-approval data collection and other key topics in HTA and health…